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 A group of Furoimidazo[3.3.3]propellane derivatives were synthesized and characterized. 
 The new compounds show ability to bind the Calf Thymus DNA (CT-DNA) in a non-
intercalative mode. 
 Their DNA groove binding was suggested using various spectroscopic techniques. 
 5c, 5d and 5f exhibited similar activity to cisplatin in inhibiting the proliferation of the 
A549 NSCLC cell line. 






A large number of natural products containing the propellane scaffold have been reported to 
exhibit cytotoxicity against several cancers; however, their mechanism of action is still unknown. 
Anticancer drugs targeting DNA are mainly composed of small planar molecule/s that can 
interact with the DNA helix, causing DNA malfunction and cell death. The aim of this study was 
to design and synthesize propellane derivatives that can act as DNA intercalators and/or groove 
binders. The unique structure of the propellane derivatives and their ability to display planar 
ligands with numerous possible geometries renders them potential starting points to design new 
drugs targeting DNA in cancer cells.  New substituted furo-imidazo[3.3.3]propellanes were 
synthesized via the reaction of substituted alkenylidene-hydrazinecarbothioamides with 2-(1,3-
dioxo-2,3-dihydro-1H-2-ylidene)propanedinitrile in tetrahydrofuran at room temperature. The 
structures of the products were confirmed by a combination of elemental analysis, NMR, ESI-
MS, IR and single crystal X-ray analysis.  Interestingly, 5c, 5d and 5f showed an ability to 
interact with Calf Thymus DNA (CT-DNA). Their DNA-binding mode was investigated using a 
combination of absorption spectroscopy, DNA melting, viscosity, CD spectroscopy 
measurements, as well as competitive binding studies with several dyes. Their cytotoxicity was 
evaluated against the NCI-60 panel of cancer cell lines. 5c, 5d and 5f exhibited similar anti-
proliferative activity against the A549 non-small cell lung cancer (NSCLC) cell line. Further 
mechanistic studies revealed their ability to induce DNA damage in the A549 cell line, as well as 
apoptosis, evidenced by elevated Annexin V expression, enhanced caspase 3/7 activation and 
PARP cleavage. In this study, we present the potential for designing novel propellanes to 
provoke cytotoxic activity, likely through DNA binding-induced DNA damage and apoptosis. 
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Propellanes are tricyclic entities with a central single bond surrounded by three small to 
medium rings. Since their discovery 53 years ago, their unusual structure has initiated a great 
interest in many fields, especially in life sciences because of their presence in several natural 
products and their various biological activities.1 Although, there are over 10,000 
representatives of this chemical class, new propellane-containing natural products still being 
discovered, with unique structures and activity profiles.1 Several propellanes exhibiting 
antiviral,2 antifungal,3 antibiotic4,5 and anticancer6,7,8,9 activities have been previously 
described.  For example, Dichrocephone B, that was isolated from Dichrocephala benthamii, 
contains a [3.3.3] propellane core structure fused to a unique oxetane ring (Figure 1A), 
exhibits significant cytotoxicity against human oral squamous carcinoma cells (KB), human 
cervical cancer cells (HeLa), and non-small-cell lung carcinoma cells (A549), with IC50 values 
of 3.3, 4.1, and 4.5 µM, respectively. 8 Diepoxin δ which was isolated from the fungus 
Nattrassia Mangiferae (Figure 1B) inhibits the ability of human fibrosarcoma cells (HT1080) 
to invade through a matrigel membrane with an IC50 of 0.75 µM.
7 Another example of 
propellanes with unique structures are Epicochalasines A and B, they were isolated from the 
liquid culture broth of the fungus Aspergillus flavipes.  Their structures have both an 
adamantane-like structure, as well as a [4.4.3] propellane moiety with 19 stereogenic centers. 
These compounds have been reported to induce cell cycle arrest in an HL60 leukemia cell line 
and apoptosis in both HL60 and NB4 leukemia cell lines [9]. Although there are several 
reports of propellane natural products with considerable cytotoxicity and antitumor activities, 
little is known about their mechanism of action or their actual targets in cancer cells.1  
 
DNA is a major target of various anticancer drug discovery efforts.10 Interaction of small planar 
aromatic or heteroaromatic molecules with DNA in cancer cells, may cause lengthening, 
stiffening or unwinding of the DNA helix, inhibit DNA replication, and induce DNA 
damage.11,12 and block cell division which finally can lead to cell death.13 Generally, drug-DNA 
interaction occurs through three possible noncovalent modes: intercalation, groove binding and 
external electrostatic effects. Intercalators bind reversibly by inserting a planar aromatic 
pharmacophore between adjacent base pairs of double-stranded DNA, which in turn can lead to 
antitumor activity.14,15  For example, the metallo-intercalators contain planar, positively charged, 
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polycyclic aromatic ligands.16 They bind DNA through insertion between the planar bases.17 
Several metallo-intercalators are already used as cancer therapeutics including cisplatin, 
carboplatin, oxaliplatin and nedaplatin.18 In the same time, targeting the DNA minor groove can 
be less challenging; the small width of the groove stabilizes the binding by providing several van 
der Waal’s interactions and/or hydrogen bonding with the nucleobases.19 Interestingly, several 
natural products have been known to bind the DNA minor groove, including chromomycin, 
actinomycin D, distamycin, netropsin, and Hoechst 33258.20,21 
Here we hypothesis that propellane derivatives designed to carry planar aromatic or non-
aromatic ligands can potentially act as DNA intercalators or minor groove binders with 
promising anti-tumor activity. Several methods are reported for the synthesis of 
heterocylic[3.3.3]propellanes. Oxa-aza[3.3.3]propellanes were synthesized by Alizadeh et al. 
4,22,23,24, Yavari et al.25, Chen et al.26, and Zhang et al.27 Hassan et al. reported the formation of 
oxaaza- and bis-oxathia-aza[3.3.3]propellanes via nucleophilic addition of symmetrical and 
unsymmetrical N1,N2-disubstituted-1,2-dicarbothioamides on dicyanomethylene-1,3-indanedione 





Figure 1. Molecular structure of the propellane derivatives Dichrocephone B (A) and Diepoxin δ (B), 
reported to exhibit cytotoxic activity against several cancers7,8. (C) The crystal structure of the new 
propellane derivative 5b. 
 
Due to our continuous interest in the design and synthesis of new heterocycles with antitumor 
activity,30,31 in this study we synthesized a new group of hetero[3.3.3]propellanes by reacting 
heteroyl-hydrazinecarbothioamides with 1 to give furo-imidazo[3.3.3]propellanes.32 Also, 
nucleophillic addition of thiocarbohydrazide derivatives with 1 gave furo-
imidazo[3.3.3]propellanes.33 The ability of the new compounds to interact with DNA was 
examined using several biophysical and biochemical techniques. The cytotoxicity of the 
compounds towards the NCI-60 panel of cancer cell lines was determined. And the molecular 
mechanism of three of the new derivatives was further investigated in the A549 non-small cell 
lung cancer cell line. 
 
2. Results and discussion  
2.1. Chemistry  
The main purpose of this project was to design a new group of DNA-targeting small molecules 
using the propellane scaffold. The propellane should provide planar, polyaromatic ligands with 
enough hydrophobicity to extend into the base-stack of the DNA and/or fit into the DNA minor 
groove. (Figure 1 and scheme 1).  
 





In order to synthesize such derivatives, initially we investigated the reactions of substituted 
(ylidenehydrazinecarbothioamides) 2a-g bearing a selection of aryl, alkyl, alkenyl and 
heterocyclic substituents with 1 (Scheme 1). Under room temperature and atmospheric air, a 
mixture of dicyanomethylene-1,3-indanedione (1, 1.25 mmol) and alkenylidene-
hydrazinecarbothioamides (2a-g, 1.0 mmol) was stirred in THF for 52-72 hrs. TLC analysis 
suggested the complete disappearance of compounds 1 and 2. We found that furo-
imidazo[3.3.3]propellanes 5a-g were obtained as a colourless crystals in 71-84% yields.  
The mass spectrum of 5b, as an example displayed the molecular ion peak at m/z = 456 (11%), 
which is in agreement with the proposed structure and shows clearly the addition of one 
molecule of 2b to one molecule of 1 without any elimination. The IR spectrum of 5b in KBr 
shows a broad band at 3443-3400 cm-1 due to the NH2 group, sharp bands at 2196 and 1728 cm
-1, 
characteristic of a conjugated nitrile and indeno-CO group, respectively. Two absorption bands 
at 1371 and 987 cm-1 (C=S and C-N str.) were observed as well as a characteristic band for C-O-
C at 1102 cm-1. The 1H-NMR spectrum of 5b, exhibited a broad exchangeable signal with two 
protons at 8.50-8.52 ppm due to the NH2 group. A triplet at 0.92-0.96 ppm due to the CH3 group 
with coupling constant (J = 7.61 Hz). Two upfield multiplets at 1.48-1.54 and 2.28-2.31 are due 
to CH2-CH2, whereas a downfield multiplet at 6.36-6.39 corresponds to CH=CH, as well as to 
the aromatic protons.  In the 13C-NMR spectrum of 5b signals at 189.81, 178.93, and 154.06 are 
due to indeno-CO, thioxo and CH=N groups, respectively. Two peaks at δc = 49.58 (furan-C3), 
and 168.17 (furan-C2) are in accordance with the observed trends in δ values for carbon atoms in 
‘push-pull’ alkenes.34,35 Further signals at 81.45 (furan-C4), 103.86 (furan-C5), 110.0 and 115.70 
(CH=CH). Three signals at 13.46, 21.24 and 34.32 correspond to the CH3CH2CH2 moiety. 
As it is difficult to assess the correct structure based on the NMR spectral data, the structure of 
these compounds was unequivocally resolved by single crystal X-ray analysis. Specifically, the 
structure of 2-amino-11((1E,2E)-hex-2-en-1-ylidene)-amino)-4-oxo-9-(pyridyl-3-yl)-10-thioxo-
4H-3a,8b-(epiminomethanoimino)-indeno[1,2-b]furan-3-carbonitrile (5b) was established 
unambiguously by single crystal X-ray analysis, which confirmed the presence of a propellane 
system (Figure 1C and Tables S1-S7 in the supporting information). The X-ray crystal structure 
of 5b clearly shows that the (C4)-(C8) bond length of 1.536 (4) Å has a C-C single bond 
character and is shared by three different rings C4-C8-N7-C6-N5, C4-C8-O1-C2-C3 and C4-C8-
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C9-C4-C15. The bond length C(6)-S(6) = 1.658 (3) Å and has C=S (1.645 Å) double bond 
character. The sums of the angles around C(4) and C(8) are  319o and 337o, respectively 
revealing that restrained around C4 and C8.  
Compounds 2a-g may react either with their sulphur atom, N2 or N4 as nucleophilic sites. On the 
other hand, it has been reported that the methine carbon of 2a-g had to act as a nucleophile in the 
sense of an "umpolung."36 Thus, several options for interaction between 1 and 2a-g may be 
expected. It is probable that the products 5a-g are formed from one of the four labile 1:1 adducts. 
Several alternative structures can be suggested (Figure 2), but some of these were ruled out based 
on the 13C-NMR spectral data. Comparison of the 1H and 13C-NMR for the isomers 5-8 showed 
that propellanes 6 and 7 (Figure 2) could be ruled out. Therefore, X-ray analysis may serve as a 
useful supplementary tool in determining the correct structure, and confirm that we have the 
propellane-type structures 5a-g rather than 8a-g.  
 
Figure.2 Structures of possible isomers of compound 5. 
It was found that the reaction conditions such as solvent, catalyst, temperature play an important 
role on the reaction efficiency. Different solvents were investigated, and it was found that 
tetrahydrofuran (THF) was superior compared to chlorobenzene, acetonitrile, dichloromethane 
and DMF. The effect of different basic media was investigated. THF without any additions 
showed high activity, while others such as EtOH/(Et)3N and EtOH/piperidine were less effective. 
Increasing the amount of 1 to 1.5 mmol or 2 mmol led to a lower yield.  High product yield was 
obtained in the presence of air. Only trace amounts of product were formed when the reaction 
was performed under nitrogen or argon. The reaction was carried out at different temperatures 
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with THF as the solvent, but low product conversions were observed. Using alkenylidene-
hydrazinecarbothioamides with benzyl, allyl, pyridyl and phenyl derivatives, the observed 
products 5a-g were generated in 71-84% yields. These results indicate that both electronic and 
steric factors have no significant influence on the efficiency of the reaction. To rationalize the 
formation of propellanes 5a-g as depicted in scheme 1. The attack of the 2NH group of 2a-g on 
the C=C double bond of 1 affords the adduct 4a-g via intermediate 3a-g. Intramolecular 
nucleophilic attack of the OH on the imino group, affords furo-imidazo[3.3.3]propellanes 5a-g 
(Scheme 1). 
 
2.2. Biological investigation 
2.2.1 Anti-proliferative investigation against 60 cancer cell lines at the NCI 
The selected compounds were subjected to in vitro anticancer assays against tumor cells in a full 
panel of 60 cell lines derived from nine different cancer types (leukemia, lung, colon, CNS, 
melanoma, ovarian, renal, prostate and breast cancers). The compounds were added at single 
concentration of 10-5 M and the culture was incubated for 48 h. Growth inhibition percent is 
illustrated in Tables 1 and Table S9. 5a, 5b, 5e and 5g exhibited less anticancer activities (As 
shown in the supporting information, Table S8) if compared to 5c, 5d and 5f (Shown down in 
Table 1). 
 
Table 1. % Growth inhibition of compounds 5c, 5d and 5f. 
Panel/Cell Line 
% Growth Inhibition 
Panel/Cell Line 
% Growth Inhibition 
Compound Compound 
5c 5d 5f 5c 5d 5f 
Leukemia Melanoma 
CCRF-CEM 40.64 -0.22 20.48 LOX IMVI 25.61 5.8 10.87 
HL-60(TB) 29.58 1.34 38.21 MALME-3M 4.81 -4.03 5.73 
K-562 32.42 7.18 50.66 M14 40.08 7.13 24.61 
MOLT-4 38.9 11.42 34.78 MDA-MB-435 24.92 5.38 22.95 
RPMI-8226 48.96 19.75 44.48 SK-MEL-2 10.03 -6.35 0.73 
SR 11.28 1.58 39.13 SK-MEL-28 8.57 -10.44 5.82 
Non-Small Cell Lung Cancer SK-MEL-5 29.89 1.76 31.01 
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A549/ATCC 39.14 11.24 45.14 UACC-257 2.92 1.42 30.59 
EKVX 45.94 17.74 13.24 UACC-62 33.69 15.86 28.42 
HOP-62 29.11 15.01 2.89 Ovarian Cancer 
HOP-92 21.85 17.02 16.19 IGROV1 19 -5.64 1.44 
NCI-H226 37.29 1.65 15.64 OVCAR-3 --- 1.23 18.03 
NCI-H23 21.39 5.79 6.86 OVCAR-4 28.3 6.36 21.38 
NCI-H322M 15.54 8.05 -0.13 OVCAR-5 15.26 -0.62 7.95 
NCI-H460 22.73 -6.31 38.84 OVCAR-8 20.76 6.85 37.13 
NCI-H522 43.07 40.92 4.23 NCI/ADR-RES 19.47 -3.89 5.59 
Colon Cancer SK-OV-3 18.61 11.82 1.64 
COLO 205 6.67 -14.94 28.99 Renal Cancer 
HCC-2998 6.4 -9.24 14.04 786-0 25.18 2.86 12.87 
HCT-116 48.8 5.9 48.64 A498 15.07 15.4 16.67 
HCT-15 38.9 18.27 31.67 ACHN 72.83 4.67 6.49 
HT29 31.43 17.77 63.81 CAKI-1 ----- ----- ----- 
KM12 ----- -1.93 32.87 RXF 393 28.4 -2.11 25.4 
SW-620 2.92 -11.86 21.43 SN12C 11.57 3.69 31.97 
CNS cancer TK-10 3.2 -12.49 10.36 
SF-268 ------ 5.69 8.88 UO-31 54.99 38.03 61.91 
SF-295 33.22 11.51 34.62 Breast Cancer 
SF-539 11.92 2.56 0.75 MCF7 57.57 32.37 70.28 
SNB-19 5.7 0.31 22.56 MDA-MB-231 25.7 10.27 11.47 
SNB-75 34.78 29.2 9.78 HS 578T 20.95 4.66 21.21 
U251 27.74 0.31 37.8 BT-549 27.92 17.36 22.29 
Prostate Cancer T-47D 55.67 33.16 51.28 
PC-3 52.88 19.04 77.28 MDA-MB-468 30.96 -3 12.66 
DU-31 ------ -3.61 13.84         
 
As shown in Table 1, Compound 5c exhibited the best activity against renal ACHN cell line with 
percentage growth inhibition of 73%, whereas, it revealed moderate activity (≥ 40% inhibition) 
against leukemia CCRF-CEM & RPMI-8226, Non-Small Cell Lung Cancer EKVX, A549 and 
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NCI-H522, colon cancer HCT-116, prostate cancer PC-3, Melanoma M-14, renal cancer UO-31 
and breast cancer cell lines MCF7 & T-47D. Compound 5f (Table 1) showed inhibition activity 
against most cell lines, however, it exhibited significant inhibition against prostate PC-3, colon 
HT29, renal UO-31 and breast MCF7 cell lines with 77, 64, 62 and 70% inhibition respectively. 
5f inhibited the growth of the leukemia cell lines (K-562 and RPMI-8226), the non-small cell 
lung cancer cell lines (A549), the colon cancer cell line (HCT-116) and the breast cancer cell line 
(T-47D) with %inhibition > 40%. Also, 5d (Table 1) showed moderate to mild inhibition activity 
(> 30% inhibition) against the non-small cell lung cancer cell line NCI-H522, the renal cancer 
cell line UO-31 and the breast cancer cell lines MCF-7 and T47-D. 
On the other hand, Compound 5g (Supporting information Table S8) revealed relatively the 
highest growth inhibitory activity against leukemia K-562 cell line with 87% growth inhibition. 
On the other hand, compounds 5a, 5b and 5e exhibited mild to weak activity against most tested 
cell lines (Supporting information Table S8). From these results we can conclude that the 
presence of benzyl or cyclohexyl group would enhance the anti-proliferative activity especially 
upon increasing the flexibility of the compound (as in compounds 5c and 3f), this extension 
increased the potency of these compounds against most tested cells. Compounds containing 
phenyl, ethyl and pyridyl groups did not exhibit remarkable anti-proliferative activity. 
According to the screening results, we decided to go further and examine the capability of 
compounds 5c, 5d and 5f to bind Calf Thymus DNA (CT-DNA) under physiological conditions. 
 
2.2.2. DNA Interaction Studies 
To test our hypothesis that the anticancer activity of propellane derivatives can be attributed to 
its ability to interact with DNA, several experiments were performed to test the interaction and 
characterize the possible binding mode (Table 2). 
Table 2: DNA binding parameters for complexes 5c, 5d and 5f 
 












5c 0.39×105±5291 25.8±0.12 2.18 9.1±2.5 6.2±1.6 
5d 0.10×105±623.0 30.8±0.08 1.93 19.1±3.7 17.5±5.1 
5f 0.30×105±8243 25.9±0.25 1.92 33.7±5.1 15.3±8 
aDNA binding constant by UV-vis spectral method. b[Polynucleotide Phosphate]/([Bound compound]) Calculated 
from the UV-Vis titrations of compounds with ds-Polynucleotides. cChange in the melting temperature of CT-DNA. 
dThe concentration of each inhibitor needed to displace 50% DAPI or Hoechst 33258 from the DNA minor groove 




2.2.2.1 UV-Vis Spectroscopy 
Absorption spectroscopy is one of several techniques used to assess DNA-ligand binding, which 
results in double helix conformational changes that lead to UV spectrum alteration.37 The 
interaction of any ligand with a DNA helix may result in a hyperchromic or hypochromic effect, 
as well as a red or blue shift. The absorbance spectra of a buffered solution of 5c, 5d or 5f with 
different concentrations of Calf Thymus DNA (CT-DNA) revealed a consistent hypochromic 
effect over the 300–340 nm range, without any significant red or blue shift (Figure 3A-C).  Zhou 
et al, reported that the breaking of the DNA secondary structure that accompanies helix axis 
contraction is expected to produce a hyperchromic effect, while hypochromic effects can result 
from secondary structure stabilization by intercalation or groove binding.38 In addition, Lafayette 
et al and others have suggested that a combination of both a red shift and a hypochromic effect is 
indicative of an intercalation. Thus, a hypochromic effect in the absence of any red/blue shift, as 
seen with the propellane derivatives 5c, 5d and 5f, suggests the possibility of a non-intercalative 
binding mechanism (e.g. groove binding), rather than intercalation.39,40,41  
in 5d (Scheme 1).
 
 
Figure 3. Changes of UV/vis spectra of 5c (A) at 20 µM, 5d (B) at 20 µM and 5f (C) at 20 µM; upon the 
titration of CT-DNA at pH = 7, (buffer 50 mM sodium cacodylate containing 1% DMSO). Scatchard plot 





Based on these UV−vis titration curves (Figure 3A-C), the binding constants (Ka) and the n 
parameter, were calculated by fitting the absorption titration at 315 nm to the neighbor exclusion 
model of McGhee and von Hippel42,43 (as described in the methods section). As another evidence 
of a non-intercalative binding mode, the scatchard plots (r/Cf vs r) of the three compounds 
(Figure 3D-F) exhibited downward curvature, suggesting the binding of a single molecule along 
the DNA polymer without any other nearby ligand, a phenomenon that is also referred to as 
neighbor exclusion.42,43 The association constant Ka as well as the n-parameter were calculated 
using the Scatchard plot analysis (Figure 3D-F). As shown in Table 2, 5c and 5f showed 3-4 fold 
higher affinity than 5d towards CT-DNA with Ka = 0.39×10
5, 0.3×105 and 0.1×105 M-1 and n of ~ 
26, 26 and 31 respectively, the observation that can be attributed to the hydrophobicity of the 
benzyl gp in 5c and cyclohexyl gp in 5f if compared to the allyl substituent  
2.2.2.2. Thermal melting studies. 
Thermal denaturation experiments were performed to further assess the effect of the ligand 
binding on the CT-DNA helix conformation. DNA melting temperature (Tm) is the temperature 
at which half of the DNA denatures or becomes unwound. Intercalation into the helix is known 
to elevate this temperature by 5-8 °C due to the enhanced helix stability. While, the other binding 
modes (non-intercalative) as groove or electrostatic binding cause a limited changes in the DNA 
melting temperature.44,45,46,47 Denaturation of the helix was monitored by following the UV 
absorbance of the CT-DNA at 260 nm as a function of the temperature. Results shown in Figure 
4, revealed that the three propellane derivatives 5c, 5d and 5f similarly affected the CT-DNA 
double helix with limited changes in the melting temperature ΔTm of 2.18, 1.93 and 1.92 
°C 
respectively (Table 2).37,48 The results that provide further evidence for the suggested non-
intercalative binding mode of the propellane derivatives to CT-DNA. Similarly, several reports 
have shown that the groove binders do not exhibit a large increase in the melting temperature if 
compared to the intercalators. For examples: Kumar et al.45 showed that the cationic styryl dye 
DSMI that binds DNA in the minor groove did not show any effect on the melting temperature 
of CT- DNA as Tm was estimated to be 80 
°C in absence and presence of DSMI. Ma et al.46 has 
reported the binding mode of Aflatoxin B1 (AFB1) and aflatoxin G1 (AFG1) to CT-DNA to be 
mainly through the groove. The binding mode that was evidenced by showing that the AFB1 and 
AFG1 caused a limited change in CT-DNA melting temperature with ΔTm of 1 and 2 °C 
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respectively. Sarwar et al.47 have investigated the binding mode of coumarin to DNA. Tm  of CT-
DNA in absence and presence of coumarin was 66.8±1 and 68.3±1 respectively, suggesting a 
limited effect of coumarin on the DNA stability and supported their notion that coumarin 
possibly binds the minor groove of the Ct-DNA.  
 
Figure 4: Plots of the Melting curves of ct-DNA (100 µM) in absence and presence of 50 uM of 1, 2 and 
3 at pH = 7.0 (buffer 50 mM Na-cacodylate containing 1% 1,4-Dioxane). Experiments have been 





2.2.2.3. Viscosity studies. 
CT-DNA viscosity changes upon interaction with any ligand have been widely used as a marker 
for the possible binding mode in solution.49,50 If the interaction is accompanied by an increase in 
viscosity, this can be evidence of an intercalation mechanism, where the DNA helix lengthens to 
accommodate ligand binding. A decrease in viscosity results from partial intercalation that only 
causes bending or possibly shortening of the DNA helix. While, DNA groove binders are 
reported to cause limited (positive or negative) or no change in viscosity.46-47,49,51 For example the 
groove binder Hoechst 33258 does not affect the relative viscosity of CT-DNA solution as it has 
been reported to have no effect on the axial length of the DNA helix.50,52 As shown in Figure 5A, 
we followed the change in the values of relative specific viscosity (η/η0)1/3, (where η and η0 are 
the specific viscosity of CT-DNA in the presence of different doses of each propellane derivative 
or 10% 1,4-dioxane) as a function of r (r = [Ligand]/[CT-DNA], the results emphasized a very 
limited increase in the viscosity caused by the three derivatives.  The ability of the compounds to 
increase the viscosity of DNA follows the order of 5f>5c>5d, where the cyclohexane substituent 
was the most effective in enhancing viscosity compared to the benzyl or allyl derivatives. 
Although the propellane derivatives exhibited dose response viscosity enhancement, the increase 
was limited if compared to the effect of Cisplatin (Figure 5A) a known DNA intercalator 
reported to have a pronounced enhancement on CT-DNA viscosity.53 These observations suggest 
that the minor effect on viscosity of the propellanes may be a result of binding the DNA groove 
without having a drastic effect on the axial length of DNA (Figure 5A).  
 
2.2.2.4. Circular Dichroism Spectroscopy.  
Circular dichroism provides a more detailed study of the possible conformational changes that 
happen to the DNA helix upon interaction with a ligand. In this experiment, we recorded the CD 
spectra of 50 µM calf thymus DNA in the absence and presence of 20 µM of each propellane 
derivative. As expected, the CT-DNA (Figure 5B) showed two bands in the UV region, one at 
245 nm (negative band) caused by the right-handed helicity and one at 275 nm (positive band) 
due to base stacking.48,50 The interaction of CT-DNA with the three derivatives resulted in small 
increase in the intensity of the positive band of free CT-DNA while 5d is the only derivative that 
caused a limited change in the negative band (Figure 5B). Suggesting different effects of the 
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derivatives with benzyl and cyclohexyl substituents (5c and 5f) if compared to the allyl 
derivative (5d). Several reports have shown that the non-intercalative DNA binding results in 
limited to no change in the DNA CD spectra if compared to the DNA intercalators. The groove 
binding and electrostatic interaction have minor perturbation on the base stacking and helicity 
bands making them less efficient in changing the DNA helix conformation.46,47,54 Although, a 
recent study highlights the limitation of the CD technique in identifying the mode of ligand 
binding to DNA.55 The limited changes of the CD spectra that were observed by the propellane 
derivatives (Figure 5B) still suggest a non-intercalative binding mode rather than an intercalative 
one that is expected to cause a more drastic effect on the recorded Cd spectra. 
 
 
Figure 5: (A) Dose response effect of 5c, 5d, 5f and Cisplatin on the relative viscosity of CT-DNA at 
room temperature, [CT-DNA] = 300 μM. Three independent experiments were performed and average 
values are shown, the error bars represent ±SD. (B) Circular dichroism spectra of CT-DNA (50 μM) in the 
absence and presence of 5c, 5d and 5f (20 μM) at pH = 7, (buffer 50 mM sodium cacodylate containing 
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0.4% 1,4-Dioxane). The cuvette path length was 10 mm. Two independent experiments were performed 
and average values were calculated. 
 
2.2.2.5. Dye displacement assays 
These assays were performed to investigate the possible binding mode of the propellanes to the 
DNA helix. The DNA binding mode can be examined using a DNA binding dye that has a 
known, well-characterized, binding mode. Replacing such a dye by a ligand may suggest the 
ligand binding site.  Thus, intercalator ligands are expected to replace an intercalator dye, such as 
ethidium bromide (EB) or thiazole orange (TO), while a groove binder is expected to replace a 
groove binding dye, such as DAPI or Hoechst 33258.46,47,52,56,57 In this experiment, we tested the 
effect of the new propellane derivatives on the ability of EB or TO dye to intercalate with CT-
DNA and DAPI or Hoechst 33258 dye to bind the CT-DNA groove. DAPI has been reported to 
bind the DNA minor groove (in the case of A–T rich DNA) in addition to its ability to intercalate 
with the DNA (in the case of G–C rich DNA).56,58 The calf thymus DNA used in this study is 
41.9 mole % G-C and 58.1 mole % A-T, which makes DAPI to act mostly as a minor groove 
binder in this experiment.  Hoechst 33258 dye is another well-known groove-binder.42 The 
binding stoichiometry of DAPI and Hoechst 3328 with CT-DNA has been reported to be 20 base 
pairs for each dye molecule and the dissociation constants were estimated to be 5 and 3 nM 
respectively.52 Ethidium bromide and thiazole orange were reported to have binding 
stoichiometry of 1.5 base pairs for each dye molecule which is consistent among all DNA 
intercalators. Their dissociation constants were estimated to be 0.14 and 0.5 µM respectively.52,59  
Using 40 µM CT-DNA, we examined the ability of the new propellanes to displace these dyes at 
a saturating binding level (2 µM TO, EB or Hoechst 33258 and 6 µM DAPI). The addition of EB 
or TO to CT-DNA exhibited a drastic fluorescence enhancement due to their intercalation within 
the DNA base pairs. The continuous addition of different doses of each propellane did not show 
any significant change in the fluorescence intensity (Figure 6C and 6D). Suggesting the inability 
of these propellanes to replace either EB or TO from DNA helix and provide another evidence 
for the non-intercalative binding mode.46,47 In the same time and as shown in Figure 6A and 6B, 
the three propellane derivatives 5c, 5d and 5f were able to replace the minor groove binder 
Hoechst 33258 dye from CT-DNA in a dose dependent manner with EC50’s 9, 19 and 34 µM 
respectively (Table 2) as well as the DAPI dye with EC50’s of 6.2, 17.5 and 15.3 µM respectively 
(Table 2). Several previous reports have shown groove binding molecules replacing Hoechst 
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3325846,47 or DAPI56,58 dye from the minor groove of the DNA helix, resulting in decreased 
fluorescence intensity of Hoechst-DNA or DAPI-DNA system. These experiments suggest the 
binding mode of these new propellanes to be groove binding rather than intercalation, the 
observation that requires several future experiments to be confirmed. 
Figure 6: (A) % Relative fluorescence intensity of titration of CT-DNA (40 µM) and Hoechest 33258 (2 
µM) (B) CT-DNA (40 µM) and DAPI (6 µM) (C) CT-DNA (40 µM) and Thiazole Orange (2 µM) (D) 
CT-DNA (40 µM) and Ethidium Bromide (2 µM) with different doses of each inhibitor. Values represent 
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the normalized average of the fluorescence intensity recorded for three different wells per each inhibitor 
concentration. 
 
2.2.3. Anticancer activity 
The results mentioned above support our hypothesis that propellane derivatives designed to carry 
planar polycyclic ligands can interact with DNA and we provide data supporting the notion that 
they act as non-intercalative binders probably through the DNA groove.  It was therefore 
important to study the molecular mechanisms underlying the anti-proliferative effects of these 
compounds in a cancer cell model, such as the non-small cell lung cancer cell line A549. 
2.2.3.1. Propellane derivatives induce DNA damage and inhibited the growth of non-small 
cell lung cancer cell line A549.  
Induction of DNA damage is one of the major drivers of cancer cell growth arrest and death. 
Several generations of antineoplastic agents work mainly by induction of DNA damage.60 
Numerous reports have shown that some DNA minor groove binders can cause DNA damage 
even without acting as DNA alkylating agents. For example, Varadarajan et al have emphasized 
the DNA damage and cytotoxicity caused by the minor groove binding of several methyl 
sulfonate esters,60 while Bales et al have studied the mechanism of DNA damage caused by the 
minor groove binding of copper-phenanthroline conjugates in several cancer cell lines.61  
S009-131, a coumarin-chalcone hybrid, has been reported to exhibit anti-proliferative and anti-
tumour activity. Its ability to induce DNA damage resulted from its potential binding to the DNA 
minor groove. Incubation of cancer cells with S009-131 resulted in an enhanced γH2AX 
phosphorylation level (a well-known DNA damage marker) where highest expression was 
observed at 24 h.62 And finally Saini et al have introduced a small molecule named CT-1, as an 
orally active minor groove binder, it induces DNA damage in several breast cancer cell lines, 
leading to p53-dependent apoptosis and cell death.63  
To examine the effect of the newly developed groove binders on DNA damage in A549 cells, we 
treated the cells with different doses of each inhibitor for 12 hrs and then the effect of the 
inhibitors on γ-H2AX phosphorylation at Ser139 was monitored by immunoblotting. As 
mentioned earlier, γH2AX is a DNA damage response signaling protein, whose phosphorylation 
is an important marker for DNA damage.  As shown in Figure 7A, 5c, 5d and 5f induced γH2AX 
phosphorylation in a dose dependent manner, with robust induction at 25 µM although 10 µM of 
5f was enough to induce the DNA damage. Interestingly, as shown previously with other groove 
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binders, the DNA damage caused by the propellane derivatives was accompanied by cellular 
growth arrest. Figure 7B shows a dose-response suppression of A549 cell proliferation by 5c, 5d 
and 5f with IC50s of 2.2, 5.2 and 2.6 µM after 72 hours of treatment. The effect of cisplatin, a 
standard DNA intercalator, on A549 cell proliferation was examined in the same experiment 
(Figure 7B) and showed IC50s of 10 µM. The lower IC50 observed for compound 5c and 5f was 
mainly explained by their ability to induce the DNA damage at considerably lower dose than 5d 
as assessed after 12 hours of treatment and shown in Figure 6A besides their enhanced affinity 
towards DNA helix that were estimated in Table 2. The enhanced hydrophobicity of 5c and 5f 




Figure 7: The DNA binding properties of 5c, 5d and 5f induced the DNA damage and inhibited the 
proliferation of the Non-Small Cell Lung Cancer A549 cell line. (A) Whole-cell extracts of A549 cells 
treated with different doses of 5c, 5d and 5f for 12 hrs, were immunoblotted for phosphorylated DNA 
damage response signaling protein γH2AX (pH2AX-Ser139). Pan-actin was used as a loading control. 
(B) The anti-proliferative potency of 5c, 5d, 5f and Cisplatin, A549 cells were incubated with different 
doses of each compound for 72 hours and assessed the resultant impact on cell viability by the MTS assay 
(Promega) (Error bars: ± Standard Deviation (n = 3)) from which half-inhibitory (IC50± SEM) 
concentrations were derived and shown in the down table. 
 
2.2.3.2. Apoptosis induction in non-small cell lung cancer cell line A549.  
As a consequence of the DNA damage induction, apoptosis is known to be the potential route 
of cell death.64 Hoechst 33258, a minor groove binding dye, has been reported to act as a 
potent inducer of apoptosis in several human mesothelioma cell lines.65 Saini et al introduced 
a curcumin-triazole conjugate as another example of a minor groove binder that inhibited the 
viability of breast cancer cell lines by causing cell cycle arrest at the S phase and induction of 
apoptosis.63 Numerous benzimidazole derivatives have also been reported as minor groove 
binders, and for instance, 5-Phenyl-2-p-tolyl-1H-benzimidazole has been shown to induce the 
intrinsic pathway of apoptosis in leukemia cell lines by activating caspase 9 and caspase 3.66  
After justifying the ability of the new propellane derivatives as DNA damage inducers, we 
also examined their ability to trigger apoptosis.  Four doses of each derivative were tested in 
A549 cells (0, 10, 100 and 200 µM of 5c, 5d and 5f). Figure 7A represents the percentage of 
the cells that showed early and late apoptosis after 40 and 60 hrs of treatment.  It is clear that 
the three propellane derivatives induce the apoptosis of A549 cells in a dose-dependent 
manner, as judged by single cell assays using Annexin V and Caspase 3/7 activity as markers 
(visualized using the IncuCyte zoom microscope). Moreover, treatment of A549 cells with 
different doses of 5c, 5d and 5f resulted in an increase in cleaved PARP, another marker of 
apoptosis induction.67 These data support the notion that the induction of DNA damage and 





Figure 7: Treatment of 5c, 5d and 5f induced apoptosis in A549 cell line. (A) Caspase-3/7 
activity and Annexin V integration was significantly increased in the treated cells in a dose-
dependent manner. The apoptosis analysis was performed using the IncuCyte® ZOOM 
equipment with a × 10 objective at indicated time points. A549 cells were treated with different 
doses of each compound and the IncuCyte Caspase-3/7 or Annexin V reagents. Apoptotic cells 
number was normalized to the percentage area coverage (confluency) at the final time point. 
Error bars: SEM (n = 3). (B) Western blotting of lysates from A549 cells treated for 24 hours 
with 5c, 5d and 5f, immunoblotted for increased level of the apoptosis marker cleaved PARP. 




It has been reported that numerous natural products containing the propellane substructure 
exhibit cytotoxicity against several cancers. The aim of this study was to test the hypothesis that 
propellane scaffold carrying one or two planar ligands can exhibit cytotoxicity by direct 
interaction with the DNA helix. We started by designing several furo-imidazo[3.3.3]propellanes  
derivatives (5a-g) and developed a new method allowing general and effective synthesis of these 
derivatives with fairly high yields in a relatively short reaction time with easy work-up 
procedures.  It was found that solvent, temperatures and catalyst may all play a critical role on 
the reaction efficiency. Also, the electrophilic C/C double bond in the acceptor plays an 
important role on the type of nucleophilic site of addition.  Interestingly, the anti-proliferative 
activity observed by these compounds against A549 NSCLC cells is directly correlated to their 
ability to bind CT-DNA (determined using UV-Vis spectroscopy). The ability of the compounds 
to replace the minor groove binding dyes Hoechst 33258 and DAPI, without any effect on the 
intercalator dyes ethidium bromide and thiazole orange suggests that these new derivatives may 
act as groove binders rather than DNA intercalators.  This conclusion was supported by UV-Vis 
spectroscopic data, as well as thermal denaturation, viscosity and CD studies that suggested a 
non-intercalative binding mode.  Finally, the mechanism of cell death caused by these 
compounds was attributed to their DNA damaging ability and subsequent induction of apoptosis. 
In this study, we provide a new group of propellane-dependent that probably acts as DNA groove 
binders. Although several future studies are required to support this finding, these new 
derivatives may act as excellent starting points to develop new drugs that can efficiently bind 
DNA and cause cancer cell death. In addition, this is the first study that showed a possible 
mechanism for the cytotoxicity caused by propellane containing compounds, through their ability 
to interact with DNA in cancer cells.  
 
4. Material and Methods  
4.1.Chemistry 
Melting points (mp’s) were recorded on a Gallenkamp melting point apparatus (Gallenkamp, 
UK), by using open capillaries and are uncorrected. NMR data was recorded on a Bruker AM 
400 spectrophotometer (Germany), The 1H-NMR (400.13 MHz) and 13C-NMR (100.6 MHz). 
Chemical shifts were reported in ppm from tetramethylsilane using solvent resonance in CDCl3 
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or DMSO-d6 solutions as the internal standard. The 
13C-NMR signals were assigned on the basis 
of DEPT 135/90 spectra. The mass spectra were obtained on Finnigan MAT 312) (Germany) 
instrument using electron impact ionization (70 eV). The IR spectra were recorded on Bruker 
Alpha FT-IR instrument (Germany) with samples prepared as potassium bromide pellets. Thin-
layer chromatography (TLC) was performed on precoated plates (silica gel 60 Pf254), and zones 
were visualized with ultraviolet (UV) light. Elemental analyses were determined by the using an 
Elemenatar 306 (Germany). 
4.1.1. Starting materials 
Substituted alkenylidene-hydrazinecarbothioamides 2a-g were prepared by the reaction of 4-
substituted thiosemicarbazide with the proper aldehyde according to the published procedures in 
literature (2a,68 2b,69 2c,70 2d,68 and 2e70). 
 (E)-N-cyclohexyl-2-((E)-hex-2-en-1-ylidene)hydrazinecarbothioamide (2f) 
Yield: 2.35 g (93 %); colorless crystals (EtOH); mp 56-57 °C.  
IR (KBr): 3375-3446 (NH), 2928-2852 (Ali-CH), 1643 (C=N), 1517 (NH def. and C-N str.), 
1364, 982 (C=S and C-N str.) cm–1. 
1H NMR (400 MHz, CDCl3): δ = 0.90-0.94 (t, J = 7.63 Hz, 3H, CH3), 1.26-1.28 (m, 2H, CH2), 
1.45-1.48 (m, 2H, cyclic-CH2), 1.62-1.64 (m, 4H, cyclic-CH2), 1.78-1.80 (m, 4H, cyclic-CH2), 
2.14–2.18 (m, 2H, CH2), 2.21-2.24 (m, 1H, cyclic-CH), 6.12–6.14 (m, 2H, CH=CH), 7.32 (br, 1 
H, cyclohexyl-NH), 7.51-7.53 (m, 1H, CH=N), 9.74 (br, 1H, NH). 
13C NMR (100 MHz, CDCl3): δ = 13.14 (CH3), 22.11 (CH2), 25.16 (CH2), 26.08 (cyclic-CH2), 
33.42 (cyclic-CH2), 35.17 (cyclic-CH2), 41.22 (cyclic-CH), 124.86, 126.23 (CH=CH), 144.16 
(CH=N), 176.12 (C=S).  
MS: m/z (%) = 253 [M+, 23], 219 (7), 141 (6), 98 (100), 83 (33), 69 (17). 
Anal. Calcd for C13H23N3S (253.16): C, 61.62, H, 9.15; N, 16.58; S, 12.65.Found: C, 61.73; H, 
9.27; N, 16.46; S, 12.55. 
(E)-N-benzyl-2-pentylidenehydrazinecarbothioamide (2g) 
Yield: 1.99g (80 %); colorless crystals (EtOH); mp 42-43 °C.  
IR (KBr): 3362-3352 (NH), 3062 (Ar-CH), 2953-2864 (Ali-CH), 1632 (C=N), 1603 (Ar-C=C), 
1519 (NH def. and C-N str.), 1355, 973 (C=S and C–N) cm–1. 
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1H NMR (400 MHz, CDCl3): δ = 0.88-0.90 (t, J = 7.60 Hz, 3H, CH3), 1.28-1.32 (m, 2H, CH2), 
1.38-1.42 (m, 2H, CH2), 2.18-2.22 (m, 2H, CH2), 4.93 (s, 2H, CH2Ph), 7.30-7.35 (m, 3H, Ar-H), 
7.36–7.41 (m, 3H, Ar-H and CH=N), 7.58 (br, 1 H, NH-CH2Ph), 9.85 (br, 1H, NH). 
13C NMR (100 MHz, CDCl3): δ = 13.41 (CH3), 21.52 (CH2), 28.12 (CH2), 33.11 (CH2), 48.22 
(CH2Ph), 125.64, 127.12, 128.66 (Ar-CH), 137.16 (Ar-C), 148.22 (CH=N), 178.33 (C=S). 
Anal. Calcd for C13H19N3S (249.13): C, 62.61, H, 7.68; N, 16.85; S, 12.86. Found: C, 62.50; H, 
7.80; N, 16.96; S, 12.74. 
4.1.2.  Synthesis of Furo-imidazo[3.3.3]Propellanes (5a-g) 
General procedure: A stirred solution of substituted 1.0 mmol of alkenylidene-
hydrazinecarbothioamide 2a-g in dry THF (20 mL) was added to dicyanomethylene-1,3-
indanedione (1, 1.25 mmol) in dry THF (15 mL). The mixture was stirred for 3 hrs. The reddish-
brown mixture was allowed to stand for 52-72 hrs (monitored by TLC) at room temperature 
during which time colorless crystals of 5b were precipitated. The precipitate was filtered off, 
washed with 5 mL of THF, dried and recrystallized from ethanol. The other derivatives 5a,c-g 
were subjected to PLC (plate layer chromatography) using Toluene/ EtOAc (10:7). 
(3aS,8bR)-2-amino-11-((E)-((E)-hex-2-en-1-ylidene)amino)-4-oxo-9-phenyl-10-thioxo-4H-
3a,8b-(epiminomethanoimino)indeno[1,2-b]-furan-3-carbonitrile (5a). 
Yield: 3.59 g (79%); colorless crystals (EtOH); mp 250-252 °C.  
IR (KBr): 3421-3392 (NH2), 2957-2869 (Ali-CH), 2195 (CN), 1722 (CO), 1649 (C=N), 1577 
(Ar-C=C), 1367, 985 (C=S and C-N str.), 1078 (C-O-C) cm-1. 
1H NMR (400 MHz, CDCl3): δH = 0.82-0.84 (t, 3H, CH3, J = 7.62 Hz,), 1.35-1.37 (m, 2H, CH2), 
2.05-2.11 (m, 2 H, CH2), 6.45-6.48 (m, 2H, CH=CH), 7.44-7.57 (m, 5H, Ar-H and CH=N), 7.78-
7.84 (m, 3H, Ar-H), 7.86-7.91 (m, 2H, Ar-H), 8.86-8.88 (br, 2H, NH2).
 
13C NMR (100 MHz, DMSO-d6): δC = 14.52 (CH3), 22.64 (CH2), 35.87 (CH2), 47.73 (furan-C3), 
82.47 (furan-C4), 103.91 (furan-C5), 111.05, 116.14 (CH=CH), 116.75 (CN), 125.89, 126.71, 
126.93, 127.12, 127.64, 128.19, 130.37 (Ar-CH), 136.53, 137.72, 142.93 (Ar-C), 156.41 
(CH=N), 169.15 (furan-C-2), 180.17 (C=S), 190.29 (indeno-CO).  
MS: m/z (%) = 455 (M.+, 100), 301 (32), 154 (29), 135 (32). 
Anal. Calcd. for C25H21N5O2S (455.53): C, 65.92; H, 4.65; N, 15.37; S, 7.04. Found: C, 66.06; 





Yield: 3.83 g (84%); colorless crystals (EtOH); mp 244-246 °C.  
IR (KBr): 3443-3400 (NH2), 2961-2871 (Ali-CH), 2196 (CN), 1728 (CO), 1648 (C=N), 1595 
(Ar-C=C), 1371, 987 (C=S and C-N str.), 1102 (C-O-C) cm-1.  
1H NMR (400 MHz, DMSO-d6): δH = 0.92-0.96 (t, 3H, CH3, J = 7.61 Hz,), 1.48-1.54 (m, 2H, 
CH2), 2.28-2.31 (m, 2H, CH2), 6.36-6.39 (m, 2H, CH=CH), 7.60-7.61 (m, 3H, Ar-H and CH=N), 
7.75-7.78 (m, 2H, Ar-H),  7.79-7.81 (m, 2H, Ar-H), 7.99-8.02 (m, 1H, Ar-H), 8.50-8.52 (br, 2H, 
NH2), 8.71-8.72 (m, 1H, Ar-H).
 
13C NMR (100 MHz, DMSO-d6): δC = 13.46 (CH3), 21.24, 34.32 (CH2), 49.58 (furan-C-3), 
81.45 (furan-C-4), 103.86 (furan-C-5), 110.0, 115.7 (CH=CH), 116.64 (CN), 124.25, 124.64, 
125.99, 126.94, 132.78, 134.42, 137.09, 140.81(Ar-CH), 139.22, 141.36, 146.39 (Ar-C), 154.06 
(CH=N), 168.17 (furan-C-2), 178.93 (C=S), 189.81 (indeno-CO).  
MS: m/z (%) = 456 (M.+, 11), 414 (8), 320 (54), 154 (100), 136 (72).  
Anal. Calcd. for C24H20N6O2S (456.52): C, 63.14; H, 4.42; N, 18.41; S, 7.02. Found: C, 62.97; 
H, 4.51; N, 18.54; S, 6.89. 
3aS,8bR)-2-amino-9-benzyl-11-((E)-((E)-hex-2-en-1-ylidene)amino)-4-oxo-10-thioxo-4H-
3a,8b-(epiminomethanoimino)indeno[1,2-b]furan-3-carbonitrile (5c) 
Yield: 3.61g (77%); colorless crystals (EtOH); mp 236-238 °C.  
IR (KBr): 3422-3390 (NH2), 2959-2870 (Ali-CH), 2196 (CN), 1727 (CO), 1647 (C=N), 1603 
(Ar-C=C), 1377, 940 (C=S and C-N str.), 1074 (C-O-C) cm-1.  
1H NMR (400 MHz, CDCl3): δH = 0.87-0.91 (t, 3H, CH3, J = 7.63 Hz,), 1.39-1.41 (m, 2H, CH2), 
2.09-2.11 (m, 2 H, CH2), 5.15 (s, 2H, CH2Ph), 6.17-6.30 (m, 2H, CH=CH), 7.00-7.19 (m, 3H, 
Ar-H), 7.55–7.75 (m, 5H, Ar-H and CH=N), 7.80-7.92 (m, 2H, Ar-H), 8.75-8.76 (br, 2H, NH2). 
 
13C NMR (100 MHz, CDCl3): δC = 14.54 (CH3), 22.45 (CH2), 35.86 (CH2), 48.42 (CH2Ph), 
48.77 (furan-C3), 82.03 (furan-C4), 105.53 (furan-C5), 110.7, 116.0 (CH=CH), 116.82 (CN), 
125.22, 125.78, 125.87, 127.04, 127.64, 129.35, 132.82 (Ar-CH), 136.61, 137.38, 144.58 (Ar-C), 
154.65 (CH=N), 169.81 (furan-C2), 181.03 (C=S), 190.01 (indeno-CO).  
MS: m/z (%) = 469 (M.+, 100), 427 (91, 320 (36), 149 (64), 91 (81), 77 (55).  
Anal. Calcd. for C26H23N5O2S (469.56): C, 66.50; H, 4.94; N, 14.91; S, 6.83. Found: C, 66.62; 





Yield: 3.06g (73%); colorless crystals (EtOH); mp 190-191 °C.  
IR (KBr): 3403-3332 (NH2), 2960-2870 (Ali-CH), 2198 (CN), 1720 (CO), 1649 (C=N), 1604 
(Ar-C=C), 1373, 935 (C=S and C-N str.), 1092 (C-O-C) cm-1.  
1H NMR (400 MHz, CDCl3): δH = 0.82-0.85 (t, 3H, CH3, J = 7.63 Hz,), 1.37-1.39 (m, 2H, CH2), 
2.09-2.12 (m, 2H, CH2), 4.28-4.32 (m, 2H, allyl-CH2N), 5.04-5.08 (m, 2H, allyl-CH2=), 5.77-
5.79 (m, 1H, allyl-CH=), 6.06-6.16 (m, 2H, CH=CH), 7.57–7.61 (m, 3H, Ar-H and CH=N), 
7.73-7.75 (m, 1H, Ar-H),7.84-7.86 (m, 1H, Ar-H), 8.20-8.23 (br, 2H, NH2) 
13C NMR (100 MHz, CDCl3): δC = 14.54 (CH3), 22.72 (CH2), 35.85 (CH2), 47.75 (allyl-CH2N), 
47.72 (furan-C3), 79.66 (furan-C4), 104.0 (furan-C5),111.12, 116.31 (CH=CH), 116.91 (CN), 
118.41 (allyl-CH2=), 125.99, 127.02, 128.79, 132.85 (Ar-CH), 134.82 (allyl-CH=), 137.02, 
144.86 (Ar-C), 155.05 (CH=N), 169.50 (furan-C2), 181.12 (C=S), 190.70 (indeno-CO).  
MS: m/z (%) = 419 (M.+, 100), 377 (71), 320 (12), 265 (12), 154 (43), 99 (11).  
Anal. Calcd. for C22H21N5O2S (419.50): C, 62.99; H, 5.05; N, 16.69; S, 7.64. Found: C, 63.16; 
H, 4.91; N, 16.54; S, 7.72. 
(3aS,8bR)-2-amino-9-ethyl-11-((E)-((E)-hex-2-en-1-ylidene)amino)-4-oxo-10-thioxo-4H-
3a,8b-(epiminomethanoimino)indeno[1,2-b]furan-3-carbonitrile (5e) 
Yield: 2.89g (71%); colorless crystals (EtOH); mp 200-202°C.  
IR (KBr): 3409-3321 (NH2), 2961-2870 (Ali-CH), 2199 (CN), 1721 (CO), 1647 (C=N), 1603 
(Ar-C=C), 1376, 934 (C=S and C-N str.), 1084 (C-O-C) cm-1.  
1H NMR (400 MHz, DMSO-d6): δH = 0.85-0.88 (t, 3H, CH3, J = 7.65 Hz,), 1.13-1.17 (t, 3H, 
CH3, J = 6.71 Hz,), 1.40-1.45 (m, 2H, CH2), 2.14-2.19 (m, 2H, CH2), 3.83-3.87 (q, 2H, CH2, J = 
6.71 Hz,), 6.18-6.30 (m, 2H, CH=CH), 7.82-7.85 (m, 3H, Ar-H and CH=N), 7.94-7.97 (m, 2H, 
Ar-H), 8.21-8.24 (br, 2H, NH2).  
13C NMR (100 MHz, DMSO-d6): δc = 13.21 (CH3), 13.48 (CH3), 21.32 (CH2), 34.23 (CH2), 
44.16 (CH2), 48.02 (furan-C-3), 78.00 (furan-C-4), 104.39 (furan-C-5), 112.0, 115.91 (CH=CH), 
116.12 (CN), 125.17, 125.60, 127.58, 128.32 (Ar-CH), 137.28, 144.51 (Ar-C), 157.02 (CH=N), 
165.83 (furan-C-2), 179.76 (C=S), 191.08 (indeno-CO).  
MS: m/z (%) = 407 (M.+, 100), 320 (44), 253 (26), 154 (63), 87 (24).  
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Anal. Calcd. for C21H21N5O2S (407.49): C, 61.90; H, 5.19; N, 17.19; S, 7.87. Found: C, 62.02; 
H, 5.23; N, 17.11; S, 7.93. 
(3aS,8bR)-2-amino-9-cyclohexyl-11-((E)-((E)-hex-2-en-1-ylidene)amino)-4-oxo-10-thioxo-
4H-3a,8b-(epiminomethanoimino)indeno[1,2-b]-furan-3-carbonitrile (5f) 
Yield: 3.41g (74%); colorless crystals (EtOH); mp 205-207°C.  
IR (KBr): 3416-3328 (NH2), 2931-2856 (Ali-CH), 2196 (CN), 1725 (CO), 1650 (C=N), 1601 
(Ar-C=C), 1347, 981 (C=S and C-N str.), 1101 (C-O-C) cm-1.  
1H NMR (400 MHz, CDCl3): δH = 0.84-0.86 (t, 3H, CH3, J = 7.66 Hz,), 1.29-1.39 (m, 4H, 
cyclohexyl-CH2), 1.41-1.42 (m, 2H, CH2), 1.65-1.70 (m, 4H, cyclohexyl-CH2), 1.80-1.83 (m, 
2H, cyclohexyl-CH2), 2.07-2.11 (m, 2H, CH2), 2.15-2.17 (m, 1H, cyclohexyl-CH), 6.16-6.18 (m, 
2H, CH=CH), 7.58-7.66 (m, 3H, Ar-H and CH=N), 7.77-7.89 (m, 2H, Ar-H), 8.70-8.73 (br, 2H, 
NH2).  
13C NMR (100 MHz, DMSO-d6): δc = 14.52 (CH3), 22.80 (CH2), 27.24, 30.17, 35.83 
(cyclohexyl-CH2), 35.97 (CH2), 48.11 (furan-C-3), 59.62 (cyclohexyl-CH), 80.50 (furan-C-4), 
104.12 (furan-C-5), 111.64, 116,41 (CH=CH) 116.89 (CN), 124.52, 127.16, 128.99, 132.73 (Ar-
CH), 137.33, 145.99 (Ar-C), 154.97 (CH=N), 168.79 (furan-C-2), 181.59 (C=S), 190.37 (indeno-
CO).  
MS: m/z (%) = 461 (M.+, 100), 320 (44), 32 (9), 419 (18), 392 (22), 154 (81).  
Anal. Calcd. for C25H27N5O2S (461.58): C, 65.05; H, 5.90; N, 15.17; S, 6.95. Found: C, 64.91; 
H, 5.76; N, 15.32; S, 7.07. 
(3aS,8bR)-2-amino-9-benzyl-4-oxo-11-((E)-pentylideneamino)-10-thioxo-4H-3a,8b-
(epiminomethanoimino)indeno[1,2-b]furan-3-carbonitrile (5g) 
Yield: 3.47 g (76%); colorless crystals (EtOH); mp 210-212 °C.  
IR (KBr): 3426-3339 (NH2), 2956-2866 (Ali-CH), 2194 (CN), 1725 (CO), 1651 (C=N), 1580 
(Ar-C=C), 1353, 991 (C=S and C-N str.), 1076 (C-O-C) cm-1.  
1H NMR (400 MHz, DMSO-d6): δH = 0.93-0.96 (t, 3H, CH3, J = 7.61 Hz,), 1.44-1.46 (m, 2H, 
CH2), 1.60-1.62 (m, 2H, CH2), 2.42-2.44 (m, 2H, CH2), 5.20 (s, 2H, CH2Ph), 7.09-7.21 (m, 3H, 
Ar-H), 7.75-7.83 (m, 5H, Ar-H and CH=N), 7.91-7.96 (m, 2H, Ar-H), 8.30-8.35 (br, 2H, NH2). 
 
13C NMR (100 MHz, DMSO-d6): δc = 13.45 (CH3), 21.72 (CH2), 27.35 (CH2), 32.03 (CH2), 
47.83 (CH2Ph), 49.21 (furan-C-3), 80.70 (furan-C-4), 104.87 (furan-C-5), 116.93 (CN), 125.34, 
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126.04, 127.10, 128.06, 132.65, 133.34, 135.66 (Ar-CH), 136.34, 137.28, 141.29 (Ar-C), 157.22 
(CH=N), 167.52 (furan-C-2), 180.05 (C=S), 189.96 (indeno-CO).  
MS: m/z (%) = 457 (M.+, 69), 308 (23), 153 (100).  
Anal. Calcd. for C25H23N5O2S (457.55): C, 65.63; H, 5.07; N, 15.31; S, 7.01. Found: C, 65.78; 
H, 4.91; N, 15.19; S, 6.94. 
4.1.3. Single Crystal X-ray Structure Determination of 5b: 
The single-crystal X-ray diffraction study was carried out on a Bruker D8 Venture diffractometer 
with Photon100 detector at 123(2) K using Cu-Kα radiation (λ = 1.54178 Å. Direct Methods 
(SHELXS-97)71 were used for structure solution and refinement was carried out using SHELXL-
2014 (full-matrix least-squares on F2).72 Hydrogen atoms were refined using a riding model 
(H(N) free, ). A semi-empirical absorption correction was applied. The hex-2-en-1-ylidene 
substituent is disordered. 
Compound 5b: C24H20N6O2S, Mr = 456.52 g mol
-1, colourless blocks, size 0.22 × 0.08 × 0.04 
mm, triclinic, space group P-1, a = 10.3144 (4) Ǻ, b = 10.3654 (4) Ǻ, c = 11.3719 (6) Ǻ, α = 
68.809 (2)o, β = 80.169 (2)o, γ = 80.674 (2) o, V = 1110.26 (8) Ǻ3, Z = 2, Dcalcd = 1.336 Mg m
-3, F 
(000) = 476, μ = 1.58 mm-1, Τ = 123 K, 13297 measured reflections (2θmax= 144.0
o), 4312 
independent reflections [Rint = 0.025], 297 parameters, 115 restraints, R1 [for 4002 › 2σ (I)] = 
0.073, wR2 (for all data) = 0.211, S = 1.03, largest diff. peak and hole = 1.64 e Ǻ-3/- 1.07 e Ǻ-3. 
CCDC 1875475 (5b) contains the supplementary crystallographic data for this paper. These data 
can be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
4.2. Biology 
4.2.1. Sixty cancer cell lines screening at the NCI 
The methodology of the NCI anticancer screening has been described in detail at 
(http://www.dtp.nci.nih.gov). Briefly, the anticancer assay was performed at approximately 60 
human cancer cell lines panel derived from nine different tumor types, in accordance with the 
protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda. The tested anilides 
were added to the culture at a single concentration (10-5 M) and the cultures were incubated for 
48 h. End point determinations were made with a protein binding dye, SRB. Results for each 
tested compound were reported as the percent of tumor growth of the treated cells in comparison 
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with the untreated control cells. The percentage growth was evaluated spectrophotometrically 
versus controls not treated with test agents. 
4.2.2. DNA Interaction Experiments: 
DNA preparation - CT-DNA or Deoxyribonucleic acid sodium salt from calf thymus (Type I, 
fibers) was purchased from Sigma-Aldrich and solubilized in 50 mM sodium cacodylate buffer 
(pH 7), sonicated for 30 minutes then kept in an orbital shaker for 24 hours (at 4oC) before 
filtration through 0.45 µm filter. Final molar concentration was determined by measuring the 
absorbance of the solution at λ=260 nm, using ε(CT-DNA)=6600 mmol–1 cm–2.  
Absorption spectral studies- The UV/vis spectra were obtained on Varian Cary 50 Bio 
spectrometer using quartz cuvettes (1 cm). The experiments were performed by titrating a fixed 
concentration of each compound (20 µM) with different concentrations of CT-DNA. The 
reaction was performed in 50 mM sodium cacodylate buffer (pH 7) containing 1% DMSO. The 
spectral changes upon continuous DNA titration were recorded and employed to calculate the 
binding constant (Ka) of each tested compound using both the Scatchard equation and the 
neighbor exclusion model (Eq 1) [42, 43], where Cf is the concentration of the free compound 
(probe), r is the ratio of the concentration of bound drug Cb to the total binding sites [DNA] and 
n is the binding density. All data were treated using KalediaGraph software. 
     
                                 (Eq 1) 
 
The Thermal Denaturation Studies - Thermal melting studies of CT-DNA were performed by 
following the absorption change at 260 nm as a function of temperature change using Cary 4000 
UV-Vis. The Absorbance was recorded over a temperature range of 30-90 oC with a ramp rate of 
0.5 oC min-1 in 50 mM sodium cacodylate buffer (pH 7) containing 1% 1,4-Dioxane. The melting 
temperature (Tm) was determined from the derivative plot (dA260/dT vs T) of the melting plot. 
ΔTm Values were calculated by subtracting Tm of the free CT-DNA from the Tm of the CT-
DNA-Drug complex. 
Viscosity Studies - The viscosity of 300 µM of the CT-DNA at pH = 7, (buffer 50 mM sodium 
cacodylate containing 10% 1,4-Dioxane) alone or in combination with different doses of each 
tested compounds (50, 100, 200 and 300 µM) were estimated in a final volume of 3 mL using the 
Ostwald viscometer (at 22 °C). Results were plotted as (η/η0)1/3 versus the ratio of the 
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concentration of each compound to CT-DNA (r), where η0 is the viscosity of CT-DNA alone 
while η is the viscosity of CT-DNA in the presence of each tested compound. Viscosity values 
were estimated from the observed flow time of the solution contacting CT-DNA subtracted from 
the flow time of the used buffer (buffer 50 mM sodium cacodylate containing 10% 1,4-Dioxane) 
(t0), η = (t − t0).  
Circular dichroism studies - The possible conformational alteration of CT-DNA due to the 
interaction with compounds 5c, 5d and 5f was investigated using the circular dichroism. The 
circular dichroism (CD) spectroscopic studies were performed using Jasco J-810 circular 
dichroism spectropolarimeter at 25 °C. CD spectra of the CT-DNA at a concentration of 50 µM 
were recorded at pH = 7, (buffer 50 mM sodium cacodylate containing 0.4% 1,4-Dioxane) in 
absence and presence of 20 µM of each tested compound. 
Fluorescence dye displacement assay – The assay was performed using the Victor3 V Model 
1420 plate reader from PerkinElmer (Waltham, MA). Each Dye-DNA complex were formed by 
mixing 40 µM CT-DNA with 2 µM Ethidium Bromide, 2 µM thiazole orange, 2 µM Hoechst 
33258 or 6 µM DAPI  in a buffer containing 50 mM sodium cacodylate and 2.5-5% 1,4-
Dioxane, (pH 7). Stock solutions of different doses of the tested compounds were prepared in 
the same buffer and added into the dye-DNA solution. Fluorescence emission was recorded at 
room temperature with a 1 cm light-path quartz cuvette and 10 nm slit width for both excitation 
and emission. The EB–DNA mixture was excited at 515 nm, and the emission was recorded at 
590 nm. Similarly, excitation wavelengths were 504, 345, and 344 nm for thiazole orange, DAPI 
and Hoechst 33258, respectively. The emission was recorded at 530 nm for thiazole orange and 
at 460 nm for DAPI and H33258. 
4.2.3. Anticancer activity assays: 
Cell culture –A549 cell line was cultured in RPMI (Invitrogen) supplemented with 10% (v/v) 
Fetal Bovine Serum (FBS)-US grade (Invitrogen), 1X Glutamax (Invitrogen), 100 UmL-1 
penicillin (Sigma), and 100 gmL-1 streptomycin (Sigma). Cells were cultured in a humidified 
5% CO2 incubator at 37 °C. For Western blotting, cells were seeded at 800,000-1000,000 cells 
per well in a 6-well plate and incubated for 24 hrs before treatment with DMSO or different 
doses of each compound for 12 or 24 hours.  
Western Blotting - After drug incubation, cell lysates were prepared in M-PER ™ Mammalian 
Protein Extraction Reagent (Thermo-Fisher) after washing in PBS (Invitrogen). The lysates were 
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cleared by centrifugation, and Bradford analysis (Bio-Rad) was used to measure the protein 
concentration. Lysates containing 60 µg of total protein were fractionated on a 10% SDS 
polyacrylamide gel (Bio-Rad) and transferred to Hybond-P PVDF Membrane (GE Healthcare). 
Primary antibodies were incubated overnight at 4 ºC using 1:1000 antiphospho-H2AX (Ser-139), 
rabbit mAb (Cell Signaling Technology); 1:1000 anti-H2AX (D17A3) rabbit mAb (Cell 
Signaling Technology); 1:1000 anti-PARP (46D11) rabbit mAB (Cell Signaling Technology); 
1:1000 anti-cleaved-PARP (D214) rabbit polyclonal Abs (Cell Signaling Technology); 1/2000 
anti-Vinculin (E1E9V) XP rabbit mAb (Cell Signaling Technology) and 1:5000 antiactin, clone 
4 mouse mAb (Millipore). Either anti-rabbit (Bio-Rad) or anti-mouse (Cell Signaling 
Technology) horseradish peroxidase-conjugated secondary antibodies and Western Bright ECL 
Western Blotting Reagents (Advansta) were used to develop the blots. All experiments were 
reproduced in independent experiments. All experiments were performed two times. 
Cells proliferation assays -The MTS assay (CellTiter 96® AQueous One Solution Cell 
Proliferation Assay from Promega) was used to detect the proliferation of cells following the 
manufacturer protocol. All experiments were performed in triplicate. 
IncuCyte apoptosis analysis - In each well of a 96 well plate, A549 cells were seeded (2000 
cells/well). Cells were allowed to adhere for 24 hours before treatment. Cells were treated with 
different doses of each compound in the presence of constant concentration of the lncuCyte 
Caspase-3/7 or Annexin V reagent following the manufacturer’s protocol. Cells were incubated 
and imaged in the lncuCyte® ZOOM microscope with a ×10 objective at different time points. 
The number of apoptotic cells was normalized to the percentage confluency at each time point to 
account for cell proliferation. 
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Linares, M. Journal of the American Chemical Society 2017, 139, 14947. 
(56) Ali, M. S.; Farah, M. A.; Al-Lohedan, H. A.; Al-Anazi, K. M. RSC advances 2018, 8, 9083. 
(57) Xuan, S.; Meng, Z.; Wu, X.; Wong, J.-R.; Devi, G.; Yeow, E. K. L.; Shao, F. ACS Sustainable 
Chemistry & Engineering 2016, 4, 6703. 
(58) Kikuta, E.; Aoki, S.; Kimura, E. Journal of Biological Inorganic Chemistry 2002, 7, 473. 
(59) Vardevanyan, P. O.; Antonyan, A. P.; Parsadanyan, M. A.; Shahinyan, M. A.; Hambardzumyan, L. 
A.; Torosyan, M. A.; Karapetian, A. T. Journal of the Brazilian Chemical Society 2012, 23, 2016. 
(60) Varadarajan, S.; Shah, D.; Dande, P.; Settles, S.; Chen, F.-X.; Fronza, G.; Gold, B. Biochemistry 
2003, 42, 14318. 
36 
 
(61) Bales, B. C.; Kodama, T.; Weledji, Y. N.; Pitie, M.; Meunier, B.; Greenberg, M. M. Nucleic acids 
research 2005, 33, 5371. 
(62) Ashraf, R.; Hasanain, M.; Pandey, P.; Maheshwari, M.; Singh, L. R.; Siddiqui, M. Q.; Konwar, R.; 
Sashidhara, K. V.; Sarkar, J. Scientific reports 2017, 7, 45287. 
(63) Saini, K. S.; Hamidullah; Ashraf, R.; Mandalapu, D.; Das, S.; Siddiqui, M. Q.; Dwivedi, S.; Sarkar, J.; 
Sharma, V. L.; Konwar, R. Molecular carcinogenesis 2017, 56, 1266. 
(64) Roos, W. P.; Kaina, B. Trends in molecular medicine 2006, 12, 440. 
(65) Zhang, X.; Zhang, S. C.; Sun, D.; Hu, J.; Wali, A.; Pass, H.; Fernandez-Madrid, F.; Harbut, M. R.; 
Tang, N. Plos one 2011, 6, e25822. 
(66) Hegde, M.; Kumar, K. S. S.; Thomas, E.; Ananda, H.; Raghavan, S. C.; Rangappa, K. S. RSC 
Advances 2015, 5, 93194. 
(67) Wong, D. J.; Robert, L.; Atefi, M. S.; Lassen, A.; Avarappatt, G.; Cerniglia, M.; Avramis, E.; Tsoi, J.; 
Foulad, D.; Graeber, T. G. Molecular cancer 2014, 13, 194. 
(68) Hassan, A. A.; Aly, A. A.; El‐Shaieb, K. M.; Bedair, T. M.; Braese, S.; Brown, A. B. Journal of 
Heterocyclic Chemistry 2014, 51, 674. 
(69) Hassan, A.; El-Din, A. N.; Abdel-Latif, F.; Mostafa, S.; Bräse, S. Chemical Papers 2012, 66, 295. 
(70) Hassan, A. A.; Mohamed, N. K.; Makhlouf, M. M.; Braese, S.; Nieger, M.; Hopf, H. Synthesis 2016, 
48, 3134. 
(71) Sheldrick, G. M. Acta Crystallographica Section A: Foundations of Crystallography 2008, 64, 112. 
(72) Sheldrick, G. M. Acta Crystallographica Section A: Foundations and Advances 2015, 71, 3. 
 
